Get the Stockscreener App
4.425
4.86%
0.205
Pre-market:
4.32
-0.105
-2.37%
Aptevo Therapeutics Inc stock is traded at $4.425, with a volume of 20,150.
It is up +4.86% in the last 24 hours and down -38.28% over the past month.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$4.22
Open:
$4.2426
24h Volume:
20,150
Relative Volume:
0.11
Market Cap:
$4.42M
Revenue:
$12.99M
Net Income/Loss:
$-27.95M
P/E Ratio:
-0.00133
EPS:
-3331.1893
Net Cash Flow:
$-26.12M
1W Performance:
-5.25%
1M Performance:
-38.28%
6M Performance:
-84.64%
1Y Performance:
-99.31%
1-Day Range:
$4.23
$4.47
1-Week Range:
$4.22
$4.6699
52-Week Range:
$3.95
$1,299.60
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
4.425 | 4.42M | 12.99M | -27.95M | -26.12M | -3,331.19 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
APVO Forecast, Price Target & Analyst Ratings | APTEVO THERAPEUTICS INC (NASDAQ:APVO) - ChartMill
Aptevo Therapeutics Inc.: Fundamental Analysis and Financial Ratings | AP81 | US03835L5049 - marketscreener.com
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment - Benzinga
APVO Stock Price, Quote & Chart | APTEVO THERAPEUTICS INC (NASDAQ:APVO) - ChartMill
Aptevo Therapeutics Inc.: Fundamental Analysis and Financial Ratings | APVO | US03835L4059 - marketscreener.com
Aptevo to Participate in March 2026 Conferences - ACCESS Newswire
Aptevo sends incoming CEO to Roth, spotlights trispecific drugs in Lisbon - Stock Titan
Hedge Fund Moves: Whats next for Aptevo Therapeutics Inc stock2026 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn
Aptevo Therapeutics implements 1-for-18 reverse stock split - MSN
Pharma News: Is GeoVax Labs Inc Equity Warrants ROE strong enough2026 Stock Rankings & Weekly High Conviction Ideas - baoquankhu1.vn
Aptevo shares drop despite encouraging AML trial results - MSN
Aptevo’s Mipletamig Shows 86% Clinical Benefit Rate With No CRS in Frontline AML, Promising Safety and Efficacy Data 1 - Minichart
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Aptevo Reports Promising Interim Data for AML Therapy - TipRanks
Aptevo Therapeutics: Mipletamig Shows 86% Clinical Benefit Rate with No CRS in Frontline AML - TradingView
Aptevo Therapeutics Inc Announces New Interim Data For Mipletamig In Combination With Venetoclax And Azacitidine - marketscreener.com
Aptevo Therapeutics (APVO) reports 86% benefit, no CRS in mipletamig AML data - Stock Titan
Aptevo Therapeutics (APVO) Reveals Promising Results in AML Tria - GuruFocus
Aptevo Lists Lower on New Developments - Baystreet.ca
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Aptevo Therapeutics stock tumbles despite positive trial data - Investing.com India
Aptevo Therapeutics stock tumbles despite positive trial data By Investing.com - Investing.com UK
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% - Bitget
Aptevo Therapeutics Stock Rallies On 100% Remission Rate In Acute Myeloid Leukemia Trial Cohort - MSN
Panic Selling: Is Aptevo Therapeutics Inc stock trending bullishQuarterly Investment Review & Daily Price Action Insights - baoquankhu1.vn
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
APVO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aptevo Therapeutics (NASDAQ:APVO) Upgraded at Wall Street Zen - Defense World
Retail Surge: Can Moodys Corporation reach resistance levels soon2025 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
APVO SEC FilingsAptevo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
APVOAptevo Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Aptevo Therapeutics Inc expected to post a loss of $8.10 a shareEarnings Preview - TradingView
Aptevo Therapeutics Shareholders Approve Expanded Equity Financing Capacity - TipRanks
Aptevo Therapeutics (NASDAQ: APVO) clears shareholder approval for large Yorkville equity issuance - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Seattle biotech CEO to step down, replacement named - The Business Journals
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Intellectia AI
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Drop in Short Interest - Defense World
Will Aptevo Therapeutics Inc. stock remain a Wall Street favorite2025 Performance Recap & Long-Term Investment Growth Plans - mfd.ru
Will Aptevo Therapeutics Inc. be affected by tariffsCPI Data & AI Based Buy and Sell Signals - mfd.ru
Can Aptevo Therapeutics Inc. navigate macro headwindsJuly 2025 News Drivers & Technical Buy Zone Confirmation - mfd.ru
What is Aptevo Therapeutics Inc.’s valuation compared to sectorM&A Rumor & Accurate Entry/Exit Alerts - mfd.ru
Why Aptevo Therapeutics Inc. stock attracts high net worth investorsProduct Launch & Real-Time Market Sentiment Alerts - mfd.ru
Is Aptevo Therapeutics Inc. stock a value trapQuarterly Portfolio Review & Scalable Portfolio Growth Ideas - mfd.ru
Aug Rallies: What is Aptevo Therapeutics Inc. s 5 year growth outlookJuly 2025 Setups & Verified Entry Point Detection - mfd.ru
Risk Report: Is Aptevo Therapeutics Inc impacted by rising ratesChart Signals & Safe Swing Trade Setups - baoquankhu1.vn
Is Aptevo Therapeutics Inc. stock a top momentum playSell Signal & Reliable Entry Point Alerts - mfd.ru
Aptevo Therapeutics Announces CEO Transition and Leadership Changes - The Globe and Mail
Aptevo Therapeutics announces leadership changes as CEO retires By Investing.com - Investing.com Canada
Aptevo Announces CEO Changes - marketscreener.com
Aptevo Therapeutics Inc. Announces Board and Executive Changes - marketscreener.com
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):